170 related articles for article (PubMed ID: 38679288)
1. How do the Institute for Clinical and Economic Review's Assessments of Comparative Effectiveness Compare With the German Federal Joint Committee's Assessments of Added Benefit? A Qualitative Study.
DiStefano MJ; Pearson SD; Rind DM; Zemplenyi A
Value Health; 2024 Apr; ():. PubMed ID: 38679288
[TBL] [Abstract][Full Text] [Related]
2. Examining US commercial health plans' use of The Institute for Clinical and Economic Review's reports in specialty drug coverage decisions.
Chambers JD; Enright DE; Panzer AD; Cohen JT; Ollendorf DA; Neumann PJ
J Manag Care Spec Pharm; 2023 Mar; 29(3):257-264. PubMed ID: 36840954
[No Abstract] [Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. The evolution of ICER's review process for new medical interventions and a critical review of economic evaluations (2018-2019): how stakeholders can collaborate with ICER to improve the quality of evidence in ICER's reports.
Ronquest NA; Paret K; Gould IG; Barnett CL; Mladsi DM
J Manag Care Spec Pharm; 2021 Nov; 27(11):1601-1612. PubMed ID: 34714108
[No Abstract] [Full Text] [Related]
5. HTA and economics in the United States: a systematic review of ICER reports to evaluate trends, identify factors associated with recommendations, and understand implications.
Kruzikas DT; Malone DC; Pham S; Reinsch TK; Akehurst R
J Manag Care Spec Pharm; 2020 Dec; 26(12):1548-1557. PubMed ID: 33251996
[No Abstract] [Full Text] [Related]
6. Methods for the comparative evaluation of pharmaceuticals.
Zentner A; Velasco-Garrido M; Busse R
GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
[TBL] [Abstract][Full Text] [Related]
7. The use of real-world evidence in ICER's scoping process and clinical evidence assessments.
Jiao B; Veenstra DL; Lee W; Carlson JJ; Devine B
J Manag Care Spec Pharm; 2020 Dec; 26(12):1590-1595. PubMed ID: 33251999
[No Abstract] [Full Text] [Related]
8. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
9. Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments?
Cohen JT; Silver MC; Ollendorf DA; Neumann PJ
Value Health; 2019 Dec; 22(12):1396-1401. PubMed ID: 31806196
[TBL] [Abstract][Full Text] [Related]
10. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
11. Do Research Groups Align on an Intervention's Value? Concordance of Cost-Effectiveness Findings Between the Institute for Clinical and Economic Review and Other Health System Stakeholders.
Sussman M; Yu JC; Menzin J
Appl Health Econ Health Policy; 2020 Aug; 18(4):477-489. PubMed ID: 31919779
[TBL] [Abstract][Full Text] [Related]
12. [Drug assessment: IQWiG, G-BA, and an international comparison].
Glaeske G
Internist (Berl); 2016 Jan; 57(1):94-101. PubMed ID: 26502888
[TBL] [Abstract][Full Text] [Related]
13. Intraindividual Comparisons to Determine Comparative Effectiveness: Their Relevance for G-BA's Health Technology Assessments.
Wagle JA; Flacke JP; Knoerzer D; Ruof J; Merkesdal S
Value Health; 2021 May; 24(5):744-752. PubMed ID: 33933244
[TBL] [Abstract][Full Text] [Related]
14. Exploring the feasibility of using the ICER Evidence Rating Matrix for Comparative Clinical Effectiveness in assessing treatment benefit and certainty in the clinical evidence on orphan therapies for paediatric indications.
Wex J; Szkultecka-Debek M; Drozd M; King S; Zibelnik N
Orphanet J Rare Dis; 2023 Jul; 18(1):193. PubMed ID: 37474954
[TBL] [Abstract][Full Text] [Related]
15. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
16. Nonsense on Stilts - Part 1: The ICER 2020-2023 Value Assessment Framework for Constructing Imaginary Worlds.
Langley PC
Innov Pharm; 2020; 11(1):. PubMed ID: 34017624
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
